Walczak H, Miller R E, Ariail K, Gliniak B, Griffith T S, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin R G, Rauch C T, Schuh J C, Lynch D H
Immunex Corporation, Seattle, Washington 98101, USA.
Nat Med. 1999 Feb;5(2):157-63. doi: 10.1038/5517.
To evaluate the utility of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic, we created leucine zipper (LZ) forms of human (hu) and murine (mu) TRAIL to promote and stabilize the formation of trimers. Both were biologically active, inducing apoptosis of both human and murine target cells in vitro with similar specific activities. In contrast to the fulminant hepatotoxicity of LZ-huCD95L in vivo, administration of either LZ-huTRAIL or LZ-muTRAIL did not seem toxic to normal tissues of mice. Finally, repeated treatments with LZ-huTRAIL actively suppressed growth of the TRAIL-sensitive human mammary adenocarcinoma cell line MDA-231 in CB.17 (SCID) mice, and histologic examination of tumors from SCID mice treated with LZ-huTRAIL demonstrated clear areas of apoptotic necrosis within 9-12 hours of injection.
为评估肿瘤坏死因子相关凋亡诱导配体(TRAIL)作为癌症治疗药物的效用,我们构建了人源(hu)和鼠源(mu)TRAIL的亮氨酸拉链(LZ)形式,以促进和稳定三聚体的形成。两者均具有生物活性,在体外以相似的比活性诱导人和鼠靶细胞凋亡。与LZ-huCD95L在体内的暴发性肝毒性相反,给予LZ-huTRAIL或LZ-muTRAIL似乎对小鼠正常组织无毒。最后,用LZ-huTRAIL重复治疗可有效抑制CB.17(SCID)小鼠中对TRAIL敏感的人乳腺腺癌细胞系MDA-231的生长,对接受LZ-huTRAIL治疗的SCID小鼠肿瘤进行组织学检查显示,注射后9 - 12小时内肿瘤出现明显的凋亡坏死区域。